On September 29, 2020 Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, reported the company’s participation at the Digital World CB & CDx meeting which will be held online, September 29-October 1, 2020 (Press release, Personalis, SEP 29, 2020, View Source [SID1234567755]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Personalis will present "Enabling the Expansive Interrogation of a Tumor & Its Microenvironment from a Single Sample for Translational Research and Precision Medicine," featuring the Personalis universal cancer immunogenomics platform, ImmunoID NeXT. Kedar Hastak, PhD, will present for Personalis.

Dr. Hastak will discuss challenges facing immuno-oncology translational and clinical researchers and review the importance of insights into the complex and dynamic interactions between the tumor and immune cells of the cancer microenvironment. He will present the company’s solution to these barriers, ImmunoID NeXT, that consolidates multiple biomarker assays into one, providing a multidimensional view of the tumor and its microenvironment. He will also talk about the Personalis diagnostic initiatives, NeXT Dx, which supports patient management and biomarker-driven clinical trials, and NeXT CDx, a comprehensive companion diagnostic platform.